RESOURCES FOR YOUR PATIENTS

Register for Samples

Product samples for delivery to your door with just a few clicks. Click here to register on the Sanofi Services website and order samples.

  • Lantus® SoloSTAR® pen injection for your patients

    How to use the Lantus® SoloSTAR® pen.

    Rotate injection sites from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into affected areas.

      Hi, my name is Laura. I’d like to take a few minutes to tell you what you need to know about starting Lantus® (insulin glargine injection) 100 Units/mL using the SoloSTAR® pen. You’ve taken an important step by adding Lantus® to your diabetes treatment plan. One dose of Lantus® at the same time each day works all day and all night. Prescription Lantus® is a long-acting insulin used to treat adults with type 2 diabetes and adults and pediatric patients (children 6 years and older) with type 1 diabetes for the control of high blood sugar. Do not use Lantus® to treat diabetic ketoacidosis.

      Important Safety Information. Do not take Lantus® during episodes of low blood sugar or if you are allergic to insulin or any of the inactive ingredients in Lantus®.

      The Lantus® SoloSTAR® pen delivers the dose you dial time after time. Today, I’ll be demonstrating the correct way to use the Lantus® SoloSTAR® pen.

      The Lantus® SoloSTAR® pen can fit into your daily routine. It features small, thin needles, a large print dosing window, dial-in dose, and push-button injection.

      Do not share needles, insulin pens, or syringes with others. Do NOT reuse needles.

      To demonstrate how to correctly use the SoloSTAR® pen, I’ll be taking you through these 6 steps:

      • Checking the insulin
      • Attaching the needle
      • Performing a safety test
      • Selecting the dose
      • Injecting the dose
      • Removing and discarding the needle

      Step one: check the insulin.

      If your SoloSTAR® pen is in cool storage, take it out 1 to 2 hours before you inject to allow it to warm up. Cold insulin may be painful to inject.

      First, check the label on your SoloSTAR® pen to make sure you have the correct pen and insulin. The Lantus® SoloSTAR® pen is gray with a purple injection button.

      Check the expiration date on the label of your pen. Do not use a SoloSTAR® pen after the expiration date.

      Take off the pen cap. Check the appearance of the insulin. Lantus® is a clear insulin. Do not use the pen if the insulin is cloudy, colored, or has particles.

      Step two: attach the needle.

      Do not reuse needles. Always use a new sterile needle for each injection. This helps prevent contamination and potential needle blocks.

      Wipe the rubber seal with alcohol.

      Remove the protective seal from a new needle.

      Line up the needle with the pen, and keep it straight as you attach it. Depending on the needle type, it may be pushed on or screwed on. If the needle is not kept straight while you attach it, it can damage the rubber seal and cause leakage, or break the needle.

      Step three: perform a safety test.

      Always perform the safety test before each injection.

      Performing the safety test ensures you get an accurate dose. It ensures that the pen and needle work properly, and it also removes air bubbles in the insulin.

      Select a dose of 2 units by turning the dosage selector.

      Take off the outer needle cap and keep it to remove the used needle after injection.

      Take off the inner needle cap and discard it.

      Hold the pen with the needle pointing upwards. Then tap the insulin reservoir so that any air bubbles rise up towards the needle.

      Press the button all the way in. Check if insulin comes out of the needle tip. You may have to perform the safety test several times before insulin is seen. If no insulin comes out, check for air bubbles and repeat the safety test two more times to remove them.

      If insulin still does not come out, the needle may be blocked. Change the needle and try again. If no insulin comes out after changing the needle, your SoloSTAR® pen may be damaged. Do not use it.

      Step four: select the dose.

      You can set the dose in steps of 1 unit, from a minimum of 1 unit to a maximum of 80 units. If you need a dose greater than 80 units, you should give it as two or more doses.

      Check that the dose window shows “0” following the safety test. Select your required dose. If you turn past your dose, you can turn the dial back down. Do not push the injection button while turning, as insulin will come out.

      You cannot turn the dosage selector past the number of units left in the pen. Do not force the dosage selector to turn. If what remains is less than you need, either you can inject what is remaining in the pen and complete your dose with a new SoloSTAR® pen, or you can use a new SoloSTAR® pen for your full dose.

      Step five: inject the dose.

      Use the injection method as instructed by your healthcare professional.

      You can inject Lantus® in three areas of your body

      Anywhere in your stomach area, except for a two-inch radius around your navel.

      In the fatty tissue on the outer back area of your upper arm.

      Or in your thighs. Remember, the injection site should be changed each time you inject.

      Clean the injection site with an alcohol swab. Then insert the needle into the skin. Deliver the dose by pressing the injection button in all the way. The number in the dose window will return to “0” as you inject.

      Keep the button pressed all the way in. Slowly count to 10 before you withdraw the needle from the skin. This ensures that the full dose will be delivered.

      Step six: remove and discard the needle.

      Always remove the needle after each dose and store your SoloSTAR® pen without a needle attached. This helps prevent contamination and/or infection, as well as entry of air into the insulin reservoir and leakage of insulin, which can cause inaccurate dosing.

      Put the outer needle cap back on the needle, and use it to unscrew the needle from the pen. To reduce the risk of accidental needle injury, never replace the inner needle cap. If your injection is given by another person, special caution should be taken by this person when removing and disposing of the needle. Be sure to follow recommended safety measures for removal and disposal of needles in order to reduce the risk of accidental needle injury and transmission of infectious diseases.

      Now I’m going to show you how to safely dispose of the needle.

      Used needles should be placed in sharps containers (such as red biohazard containers), hard plastic containers (such as detergent bottles), or metal containers (such as an empty coffee can). Such containers should be sealed and disposed of properly. If you are giving an injection to a third person, you should remove the needle in an approved manner to avoid needle-stick injuries.

      Always put the pen cap back on the pen before storing the pen until your next injection.

      Storing your pen.

      Please review the leaflet that came with your Lantus® prescription for complete instructions on how to use and store the Lantus® SoloSTAR® pen. If your SoloSTAR® pen is in cool storage, take it out 1 to 2 hours before you use it to allow it to warm up. Cold insulin may be painful to inject. Keep the SoloSTAR® pen out of the reach and sight of children.

      Keep your unopened SoloSTAR® pen in cool storage until first use. Cool storage is between 36 and 46 degrees Fahrenheit, or 2 and 8 degrees Celsius. Do not allow it to freeze. Do not put it next to the freezer compartment of your refrigerator, or next to a freezer pack.

      Once you take your SoloSTAR® pen out of cool storage, for use or as a spare, you can use it for up to 28 days. During this time it can be safely kept at room temperature, up to 86 degrees Fahrenheit or 30 degrees Celsius. Do not use it after this time.

      Do not use a SoloSTAR® pen after the expiration date printed on the label of the pen or the label on the carton. Protect your SoloSTAR® pen from light. Discard your used SoloSTAR® pen as required by your local authorities

      Caring for your SoloSTAR® pen.

      Protect your SoloSTAR® pen from dust and dirt. You can clean the outside of your SoloSTAR® pen by wiping it with a damp cloth. Do not soak, wash, or lubricate the pen as this may damage it. Your SoloSTAR® pen is designed to work accurately and safely. It should be handled with care. Avoid situations where the SoloSTAR® pen might be damaged. If you are concerned that your SoloSTAR® pen may be damaged, use a new one. If you have any further questions about the Lantus® SoloSTAR® pen or managing your diabetes, be sure to speak to your doctor, nurse, or pharmacist.

      Thanks for joining me on this walk through how to use the Lantus® SoloSTAR® pen. I hope that you found these instructions helpful. Now, I will present the full Important Safety Information for Lantus®.

      What is Lantus® (insulin glargine injection) 100 Units/mL?

      Prescription Lantus is a long-acting insulin used to treat adults with type 2 diabetes and adults and pediatric patients (children 6 years and older) with type 1 diabetes for the control of high blood sugar.

      Do not use Lantus to treat diabetic ketoacidosis.

      Important Safety Information

      Do not take Lantus during episodes of low blood sugar or if you are allergic to insulin or any of the inactive ingredients in Lantus.

      Do not share needles, insulin pens, or syringes with others. Do NOT reuse needles.

      Before starting Lantus, tell your doctor about all your medical conditions, including if you have liver or kidney problems, if you are pregnant or planning to become pregnant or if you are breast-feeding or planning to breast-feed.

      Change (rotate) your injection sites within the area you chose with each dose to reduce your risk of getting lipodystrophy (pitted or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites. Do not use the same spot for each injection or inject where the skin is pitted, thickened, lumpy, tender, bruised, scaly, hard, scarred or damaged.

      Heart failure can occur if you are taking insulin together with certain medicines called TZDs (thiazolidinediones), even if you have never had heart failure or other heart problems. If you already have heart failure, it may get worse while you take TZDs with Lantus. Your treatment with TZDs and Lantus may need to be changed or stopped by your doctor if you have new or worsening heart failure. Tell your doctor if you have any new or worsening symptoms of heart failure, including:

      • Shortness of breath
      • Sudden weight gain
      • Swelling of your ankles or feet

      Tell your doctor about all the medications you take, including OTC medicines, vitamins, and supplements, including herbal supplements.

      Lantus should be taken once a day at the same time every day. Test your blood sugar levels while using insulin, such as Lantus. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made cautiously and only under medical supervision.

      Do NOT dilute or mix Lantus with any other insulin or solution. It will not work as intended and you may lose blood sugar control, which could be serious. Lantus must only be used if the solution is clear and colorless with no particles visible. Always make sure you have the correct insulin before each injection.

      While using Lantus, do not drive or operate heavy machinery until you know how Lantus affects you. You should not drink alcohol or use other medicines that contain alcohol.

      The most common side effect of insulin, including Lantus, is low blood sugar (hypoglycemia), which may be serious and life threatening. It may cause harm to your heart or brain. Symptoms of serious low blood sugar may include shaking, sweating, fast heartbeat, and blurred vision.

      Lantus may cause serious side effects that can lead to death, such as severe allergic reactions. Get medical help right away if you have:

      • A rash over your whole body
      • Trouble breathing
      • A fast heartbeat
      • Sweating
      • Swelling of your face, tongue, or throat
      • Shortness of breath
      • Extreme drowsiness, dizziness, or confusion

      Other possible side effects may include swelling, weight gain, low potassium levels, injection site reactions, including changes in fat tissue at the injection site, and allergic reactions.

      Important Safety Information for Lantus® (insulin glargine injection) SoloStar®

      Lantus SoloSTAR is a disposable single-patient-use prefilled insulin pen. Please talk to your healthcare provider about proper injection technique and follow instructions in the Instruction Leaflet that accompanies the pen.

      Please see full Prescribing Information at the link on this website.

  • Print materials and support

    Select a resource below to preview or print the document

    Using the Lantus® SoloSTAR® insulin pen

    Step-by-step guide to the Lantus® SoloSTAR® insulin pen

    English

Lantus® Savings Offers

Commercially insured patients pay as low as $0 and no more than $99* for a 30-day supply. For patients without insurance there is an offer too.

Terms and Eligibility Restrictions Apply. See Below*

If your patients are controlled on Lantus®

Keep them on Lantus

Lantus is a long-acting insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus should be administered once a day at the same time every day.

Limitations of Use: Lantus is not recommended for the treatment of diabetic ketoacidosis.

Important Safety Information for Lantus®

Important Safety Information for Lantus®

Contraindications

Lantus is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and Precautions
Insulin pens, needles, or syringes must never be shared between patients. Do NOT reuse needles.

Monitor blood glucose in all patients treated with insulin. Modify insulin regimen only under medical supervision. Changes in insulin regimen including, strength, manufacturer, type, injection site or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia; sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia. Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia.

Do not dilute or mix Lantus with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus via an insulin pump or intravenously because severe hypoglycemia can occur.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus, and may be life-threatening.

Medication errors, such as accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. Patients should be instructed to always verify the insulin label before each injection.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Lantus, treat and monitor until symptoms resolve.

A reduction in the Lantus dose may be required in patients with renal or hepatic impairment.

As with all insulins, Lantus use can lead to life-threatening hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated.

Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

Drug Interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Adverse Reactions

Adverse reactions commonly associated with Lantus include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.

Important Safety Information for Lantus® SoloSTAR®

Lantus SoloSTAR is a disposable single-patient-use prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen: otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

Click here for Full Prescribing Information for Lantus.

Click here for information on Sharps Medical Waste Disposal.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

*Eligibility Restrictions & Offer Terms:

Insulins Valyou Savings Program: Sanofi insulins included in this program are: ADMELOG® (insulin lispro injection) 100 Units/mL, TOUJEO® SoloStar® (insulin glargine injection) 300 Units/mL, TOUJEO® Max SoloStar® (insulin glargine injection) 300 Units/mL, LANTUS® (insulin glargine injection) 100 Units/mL, INSULIN GLARGINE injection 100 Units/mL (U-100) and APIDRA® (insulin glulisine injection) 100 Units/mL.

This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, similar federal or state programs, including any state pharmaceutical programs, or commercial/private insurance. Only people without prescription medication insurance can apply for this offer. Void where prohibited by law. For the duration of the program, eligible patients will pay $35 per 30 Day Supply. To pay $35 per 30 Day Supply, you must fill all your Sanofi Insulin prescriptions at the same time, together each month. Not valid for SOLIQUA 100/33 (insulin glargine and lixisenatide) injection 100 Units/mL and 33 mcg/mL. When using the Insulins Valyou Savings Card, prices are guaranteed for 12 consecutive monthly fills. The Insulins Valyou Savings Program applies to the cost of medication. There are other relevant costs associated with overall treatment. Sanofi reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Upon registration, patients will receive all program details.

Sanofi US Copay Program: This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program. If you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use this savings card. Please note: The Federal Employees Health Benefits (FEHB) Program is not a federal or state government healthcare program for purposes of the savings program. Void where prohibited by law.

  • Lantus or Insulin Glargine U-100 (Winthrop): Pay as low as $0 up to $99 for a 30-day supply. Amount depends on insurance coverage. Valid up to 10 packs per fill; offer valid for 1 fill every thirty days.

Savings may vary depending on patients' out-of-pocket costs. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke or amend these programs without notice.

Important Safety Information for Lantus®

Read More

Important Safety Information for Lantus®

Contraindications

Lantus is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and Precautions
Insulin pens, needles, or syringes must never be shared between patients. Do NOT reuse needles.

Monitor blood glucose in all patients treated with insulin. Modify insulin regimen only under medical supervision. Changes in insulin regimen including, strength, manufacturer, type, injection site or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia; sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia. Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia.

Do not dilute or mix Lantus with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus via an insulin pump or intravenously because severe hypoglycemia can occur.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus, and may be life-threatening.

Medication errors, such as accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. Patients should be instructed to always verify the insulin label before each injection.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Lantus, treat and monitor until symptoms resolve.

A reduction in the Lantus dose may be required in patients with renal or hepatic impairment.

As with all insulins, Lantus use can lead to life-threatening hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated.

Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

Drug Interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Adverse Reactions

Adverse reactions commonly associated with Lantus include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.

Important Safety Information for Lantus® SoloSTAR®

Lantus SoloSTAR is a disposable single-patient-use prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen: otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

Click here for Full Prescribing Information for Lantus.

Click here for information on Sharps Medical Waste Disposal.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

*Eligibility Restrictions & Offer Terms:

Insulins Valyou Savings Program: Sanofi insulins included in this program are: ADMELOG® (insulin lispro injection) 100 Units/mL, TOUJEO® SoloStar® (insulin glargine injection) 300 Units/mL, TOUJEO® Max SoloStar® (insulin glargine injection) 300 Units/mL, LANTUS® (insulin glargine injection) 100 Units/mL, INSULIN GLARGINE injection 100 Units/mL (U-100) and APIDRA® (insulin glulisine injection) 100 Units/mL.

This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, similar federal or state programs, including any state pharmaceutical programs, or commercial/private insurance. Only people without prescription medication insurance can apply for this offer. Void where prohibited by law. For the duration of the program, eligible patients will pay $35 per 30 Day Supply. To pay $35 per 30 Day Supply, you must fill all your Sanofi Insulin prescriptions at the same time, together each month. Not valid for SOLIQUA 100/33 (insulin glargine and lixisenatide) injection 100 Units/mL and 33 mcg/mL. When using the Insulins Valyou Savings Card, prices are guaranteed for 12 consecutive monthly fills. The Insulins Valyou Savings Program applies to the cost of medication. There are other relevant costs associated with overall treatment. Sanofi reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Upon registration, patients will receive all program details.

Sanofi US Copay Program: This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program. If you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use this savings card. Please note: The Federal Employees Health Benefits (FEHB) Program is not a federal or state government healthcare program for purposes of the savings program. Void where prohibited by law.

  • Lantus or Insulin Glargine U-100 (Winthrop): Pay as low as $0 up to $99 for a 30-day supply. Amount depends on insurance coverage. Valid up to 10 packs per fill; offer valid for 1 fill every thirty days.

Savings may vary depending on patients' out-of-pocket costs. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke or amend these programs without notice.